Drug Profile
Research programme: targeted lipid transport therapeutics - Amarin
Alternative Names: AMR-102/3; AMR-103; AMR-109; Combinatorial lipids programme - Amarin; TLT programme - AmarinLatest Information Update: 05 Nov 2010
Price :
$50
*
At a glance
- Originator Amarin Corporation
- Class
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - CNS disorders
Highest Development Phases
- No development reported Cognition disorders; Memory disorders; Parkinson's disease
Most Recent Events
- 05 Nov 2010 No development reported - Preclinical for Cognition disorders in United Kingdom (unspecified route)
- 05 Nov 2010 No development reported - Preclinical for Memory disorders in United Kingdom (unspecified route)
- 05 Nov 2010 No development reported - Preclinical for Parkinson's disease in United Kingdom (unspecified route)